Cytokinetics, Incorporated filings document a specialty cardiovascular biopharmaceutical company with common stock listed on the Nasdaq Global Select Market. Its 8-K reports cover financial results, corporate presentations, MYQORZO® regulatory approvals, clinical and regulatory disclosures, and material capital-structure events such as underwriting agreements for common stock offerings.
Proxy materials describe board elections, executive compensation, auditor ratification and equity plan amendments, including matters tied to the company’s employee stock purchase plan. Other filings address governance changes, risk disclosures, registered securities, exhibits and Inline XBRL cover-page data associated with Cytokinetics’ public-company reporting obligations.
CYTK filing reports an exercise of stock options for 9,503 shares on 06/29/2026 settled for cash. The filing also lists recent Rule 10b5-1 sales by Sung Lee: 6,695 shares on 06/26/2026 for $562,380, 38,730 shares on 06/24/2026 for $3,187,328.11, and 23,906 shares on 05/05/2026 for $1,837,766.45. The Form 144 records the planned resale after option exercise and lists prior sales under a 10b5-1 plan.
Morgan Stanley Smith Barney LLC submitted a Rule 144 notice concerning proposed sales of Common stock tied to restricted stock units and prior 10b5-1 sales. The filing lists 6,695 Restricted Stock Units to be sold with a 05/31/2026 date and records prior 10b5-1 sales by Sung Lee: 38,730 shares on 06/24/2026 for $3,187,328.11 and 23,906 shares on 05/05/2026 for $1,837,766.45.
CYTK filed a Form 144 notice covering the proposed sale of 38,730 shares of common stock on 06/24/2026 following an exercise of stock options, with cash proceeds. The filing lists broker/dealer Morgan Stanley Smith Barney LLC and reports prior 10b5-1 sales of 23,906 shares on 05/05/2026 for $1,837,766.45.
CYTOKINETICS INC EVP of Research & Development Fady Ibraham Malik executed an option exercise and sale in company stock. On June 23, 2026, he exercised options to acquire 3,500 shares of common stock at $7.80 per share, then sold 3,500 shares in an open-market transaction at an average price of $79.51 per share. Following these transactions, he directly held 153,902 shares of common stock and 40,886 non-qualified stock options.
Cytokinetics Inc President & CEO Robert I. Blum reported an open-market sale of 7,500 shares of common stock at $70.46 per share. After this transaction, he directly holds 385,330 shares. In addition, 2,083 shares are held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares are held indirectly by The Brittany Blum 2003 Irrevocable Trust.
CYTOKINETICS INC EVP Research & Development Fady Ibraham Malik reported an option exercise paired with a share sale. On June 9, 2026, he exercised options to acquire 3,500 shares of common stock at $7.80 per share and sold 3,500 shares in an open-market transaction at $67.98 per share.
Following these transactions, he directly owned 153,902 shares of common stock and held 44,386 non-qualified stock options. The activity reflects converting a portion of stock options into shares and immediately selling an equivalent number of shares for cash while retaining a substantial remaining equity position.
CYTOKINETICS INC director Edward M. Kaye, MD sold shares in the company. He completed an open-market sale of 2,933 shares of Common Stock at a price of $76.09 per share. After this transaction, he directly holds 10,283 shares of Cytokinetics common stock.
CYTOKINETICS INC executive Andrew Callos reported an option exercise and share sale. On 2026-06-01, he exercised non-qualified stock options to acquire 15,000 shares of Common Stock at $23.26 per share, then sold 15,000 shares in an open-market sale at $74.08 per share.
Following these transactions, Callos directly held 58,555 shares of Common Stock. The exercised stock options were part of an award that vests over four years from grant, with 25% vesting after one year and the remainder vesting monthly over the next 36 months, subject to continued employment.
CYTOKINETICS INC director Lynne Parshall sold shares in the company. On June 1, 2026, she executed an open-market sale of 5,000 shares of Common Stock at $74.08 per share. After this transaction, she directly holds 15,784 shares of Cytokinetics common stock.